While induction of the p53-dependent impaired ribosome biogenesis checkpoint is a major mechanism of efficacy of CX-5461 in p53-wild-type tumours, activation of DDR is a key mechanism in the killing of p53-null AML and lymphoma15,19. This evidence concerns the gene TP53 and acute myeloid leukemia.